Company intelligence / Profile preview

NeuroNOS

Ownership: Private
Development stage: Preclinical

Overview

NeuroNOS has demonstrated compelling preclinical results showing that its small-molecule therapy can regulate nitric oxide levels in the brain, leading to improvements in behavioral and biological markers of autism. The company’s lead candidate, BA-102, has received FDA Orphan Drug Designation for Phelan-McDermid Syndrome. First-in-human clinical trials are planned for 2026.

Therapeutic areas: OncologyPsychiatryRare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

BA-102

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Hebrew University of Jerusalem/Yissum Technology Transfer CompanyU.S.-based contract manufacturer

Beyond the preview

Go deeper on NeuroNOS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroNOS.

Explore the full profile